Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

FILE - In this April 18, 2017 file photo, a woman with Type 2 diabetes prepares to inject herself with insulin at her home in Las Vegas. The skyrocketing price of insulin has some diabetics scrambling ...

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector ...

Gov. Gavin Newsom announced on Thursday that the first state-made insulin would be available at the start of 2026.California’s CalRx® Insulin Glargine in 3mL pen form will be $55 per five-pack. That's ...

FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau (Reuters) - U.S. generics drugmaker Mylan said on ...